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A B S T R A C T
Background: The most effective and accurate treatment of hypertensive patients reduces 
cardiovascular events and improves the quality of life.
Objective: This study compared the efficacy and safety of combined (combination therapy) 
with an angiotensin-receptor blocker (ARB) a calcium-channel blocker (CCB) (Losartan / 
Amloidipine 50/10mg) vs maximal combination doses of  ARB with hydrochlorothiazide 
(Losartan /HCTZ 100/25 mg) and maximal combination doses of  CCB with HCTZ 
(Amlodipine /HCTZ 10/25 mg)  in the management of stage 2 hypertension.
Methods: This randomized clinical trial (RTC) comprised 478 hypertensive patients with 
mean age 50.5±5.21 years, and took place between January 2010 and December 2011 in 
Vasei Hospital clinic in Sabzevar. Antihypertensive drugs were washed out after 5 days of 
discontinuation of drugs and the patients with mean blood pressure in sitting position ≥ 160 
and <200 mmHg in systole and ≥ 100 and <110 mmHg in diastole were randomized into 
three groups: Losartan / Amlodipine 50/10 mg (n =164) , Losartan / HCTZ 100/25 mg (n 
=155) and Amlodipine / HCTZ 10/25 mg (n =159). The end point was reaching the blood 
pressure below 140/90 within 56 days of treatment in each group. 
Results: There was a significant difference in systolic blood pressure reductions between 
treatment groups (P<0.001) and also there was a significant difference between groups in 
reducing diastolic blood pressure (P<0.01). The highest systolic and diastolic blood pressure 
reduction respectively was found in Amlodipine/losartane and losartane/HTCZ group. The 
ANCOVA analysis revealed that only treatment regimen had a significant effect (P=0.01) and 
other factor including Age, Gender, Diabetes Mellitus, Smoking and High serum cholesterol 
didn’t have significant effect on blood pressure reduction. 
Conclusion: ARB/CCB combination therapy reduced blood pressure more effectively than 
the maximal doses of ARB or CCB with HCTZ in stage 2 hypertensive patients within this 
period of study.
►Implication for health policy/practice/research/medical education:
The importance of hypertension management lies on choosing the best therapeutic way. In this study, a comparison between old mono therapy and 
the new combination therapy in stage 2 hypertension has been described
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Introduction 
Hypertension is one of the most common worldwide 
diseases afflicting humans and requires meticulous 
control to produce the maximum reduction in clinical 
cardiovascular end points. Approximately 26.4% of the 
adult population worldwide had hypertension in 2000, 
and this is expected to increase to 29.2% by 2025 (1). The 
prevalence of hypertension in IR Iran according to the 
latest meta-analysis study done in 1999 was 21.9 % (2). 
Hypertension treatment as a disease is an important public 
health challenge. Achieving recommended goal of blood 
pressure (BP) (BP <140/90 mmHg or BP <130/80 mmHg 
in patients with diabetes or chronic kidney disease (3)) is 
difficult in majority of patients with hypertension 4. There 
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are many drugs available for treatment of hypertension. 
The variation of Antihypertensive drugs and also extensive 
clinical studies has led medical practitioners to different 
ideas for administration of these drugs. The ideal goal is that 
drug must be efficacious, free from side-effects, enable us 
to prevent all the complications of hypertension, easy to use 
and affordable. New onset patients who are diagnosed with 
uncomplicated hypertension and no compelling indications, 
choice of first line monotherapy includes angiotensin 
converting enzyme (ACEI), angiotensin receptor blocker 
(ARB), calcium channel blocker (CCB) and diuretics (5-7). 
In patients presenting with stage 2 hypertension or beyond, 
combination therapy is recommended (8). In this study we 
evaluated the efficacy rate of combination therapy with 
ARB and CCB, versus high dose ARB or CCB combined 
with hydrochlorothiazide (HCTZ) on the patients older 
than 40 years in stage 2 hypertension.
Materials and Methods
This study was a randomized clinical trial on treatment 
of stage 2 systolic hypertension conducted at Vasei 
hospital clinic of Sabzevar city in IR Iran between January 
2010 and December 2011. The diagnosis and staging of 
arterial hypertension was based on the mean value of 
two consecutive office BP measurements that were taken 
between 17:00 and 20:00 (According to the criteria of JNC 
7, before randomization). The study design is summarized 
in Figure 1. Office measurements of systolic and 
diastolic BP were performed manually with a calibrated 
sphygmotensiophone Riester® Sphygmomanometer. In 
each visit the blood pressure was taken twice, with a 5 
minutes gap while the patient is sitting on the chair. The 
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Amlodipine/
HCTZ group 
(N=159)
Losartan/
HCTZ group
(N=155)
Amlodipine/
Losartan group
(N=164)
Total
(N=489)  P value
Age (years) 50.0±5.31 50.82±4.90 49.99±5.27 50.28±5.17 0.03
Systolic BP† (mmHg) 169.90±4.07 169.80±4.10 169.94±4.07 169.88±4.07 0.99
Diastolic BP†  (mmHg) 105.29±3.61 105.19±3.61 88.78±6.75 105.29±3.59 0.97
Table 1. Distribution of Age, Gender, History of Diabetes Mellitus, Smoking, Elevated Serum Cholesterol Levels, Systolic and 
Diastolic Blood Pressure in the Population as a Whole and Each Treatment Subgroup at Baseline.
Figure1. Study design (RCT), concluding 5 days for wash out period and 56 days controlled follow up period. Wash out period was 
considered in case of incomplete/inadequate treatment, in terms of dosage and type of the drug prior to the intervention. To overcome 
this confounding issue, we designed a protocol that prescribes routine antihypertensive drugs with proper dosage, based on individual 
indications, by the cardiologist for 5 days. The prescribed drugs were the first line treatment for hypertension based on patients’ 
past medical history, drug history and blood pressure at the time of visit. These antihypertensive drugs were Captopril, Enalapril, 
hydrochlorothiazide, and Metoprolol  Here we insist that this primary treatment was performed to ensure that all participants were not 
under the influence of previous treatments and that the patients were given standard dose of treatment before entering the main study. 
blood pressure was measured in both arms and the higher 
one is recorded. The patients avoided smoking or taking 
caffeine at least 30 min before blood pressure measurement. 
This study enrolled outpatient males and females above 40 
years-old who had stage 2 systolic hypertension, defined 
as a mean in-office sitting systolic BP (MSSBP) of 160 
mmHg or greater and less than 200 mmHg or mean sitting 
diastolic BP (MSDBP) of 100 mmHg and less than 110 
mmHg at randomization. Patients were excluded if on 
mentioned drugs, pregnant or refused to undergo follow-
up visits. Treatment was changed to other drugs within one 
week, if  patients exhibited any drug-related adverse effect. 
Other key exclusion criteria were MSSBP above 200 
mmHg or mean sitting diastolic BP (MSDBP) above 110 
mmHg at the time of enrollment, use of 4 antihypertensive 
drugs in the past 30 days, secondary hypertension, or 
resistant hypertension. Antihypertensive medication were 
washed out 5 days after discontinuation of drugs and 
eligible patients were randomized to receive Amlopres 
(Amlodipine manufactured by Alborz Darou) with maximal 
dose (5 mg bid) and low dose of Hydrochlorothiazide (25 
mg daily) (Amlodipine/HCTZ group), Losartan maximal 
dose (50 mg bid) and low dose of Hydrochlorothiazide 
(Losartan /HCTZ group) or Amlodipine 5 mg bid and 
Losartan 25 mg bid, (Amlodipine Losartan group) (Figure 
1). The aim of the study was to compare the change from 
baseline in MSSBP with the drug regimens at 8 weeks. At 
each visit, patients were expelled from the study if they 
had MSSBP above 200 mmHg or MSDBP above 110 
mmHg or hypotension (MSSBP <100 mmHg or MSDBP 
<60 mmHg) or showing any other adverse event. Patients 
were not allowed to take any other antihypertensive drug 
during the study. The study was conducted in accordance 
with the ethical principles of the Helsinki Declaration. 
Statistical Analysis
The Statistical Package for the Social Sciences (SPSS) 
program version 19.0 was used to perform the statistical 
analyses. Descriptive statistics were used to show the 
frequencies and percentages. Systolic and diastolic 
blood pressure measurements and percentage of systolic 
and diastolic blood pressure reduction were shown as 
Mean±SD. Pared student t-test was performed to compare 
baseline blood pressure readings with the readings after 
intervention and also one-way ANOVA was performed to 
compare study parameters between each treatment groups. 
Chi-square was used to compare gender, history of smoking 
and high serum cholesterol between treatment groups. The 
analysis of covariance (ANCOVA) for repeated measures 
was performed to identify the interaction between study 
categories and systolic and diastolic blood pressure 
changes.  Confidence interval was considered as 0.95 and 
p values lesser than 0.05 were considered as significant.
Results
Among 478 hypertensive cases, the mean age was 
50.27±5.17 years (Median age was 50 years and IQR 
was 9 years). Table 1 presents systolic and diastolic blood 
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Age Systolic BP Diastolic BP
Gender
Male 50.1±5.3 170.0±4.1 105.4±3.5
Female 50.8±5.2 169.9±4.1 105.3±3.6
P value 0.18 0.79 0.92
Diabetes mellitus
Yes 50.4±5.5 169.9±4.1 105.5±3.6
No 50.5±5.2 169.9±4.1 105.3±3.6
P value 0.90 0.88 0.59
Smoking
Yes 50.1±5.3 169.7±4.0 105.7±3.5
No 50.6±5.3 170.0±4.1 105.23±3.61
P value 0.44 0.49 0.22
 Elevated serum
cholesterol levels
Yes 50.5±5.4 169.7±4.13 105.5±3.6
No 50.4±5.2 170.0±4.05 105.3±3.6
P value 0.86 0.58 0.52
Metabolic syndrome
Yes 50.2±5.2 170.0±4.29 104.9±3.6
No 50.5±5.3 169.9±4.01 105.4±3.6
P value 0.57 0.80 0.24
Table 2. Comparison of Study Variables Among Different Categories
Amlodipine /HCTZ
(N†=159)
Amlodipine/Losartan
(N†=164)
Losartan /HTCZ
(N†=155)
Baseline After Baseline After Baseline After
Systolic BP 169.9±4.1 137.7±5.6 169.9±4.1 135.0±5.4 169.8±4.1 140.6±8.5
P value <0.001 <0.001 <0.001
Systolic BP reduction (%) 32.17±8.58 (18.9%) 35.0±3.6 (20.5%) 29.7±9.4 (17.5%)
 Diastolic BP 105.3±3.6 88.9±6.2 88.8±6.8 84.67±4.4 105.2±3.6 89.1±6.8
P value <0.001 <0.001 <0.001
Diastolic BP reduction (%) 32.5±8.4 (30.9%) 29.6±6.2 (28.2%) 34.8±9.2 (33.3%)
Table3. Comparison of Systolic and Diastolic Blood Pressure at Baseline and after Treatment
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pressures and patients’ demographic data. There was 
no significant differences between the three treatment 
groups in regard to gender, history of diabetes mellitus 
(DM), smoking and elevated serum cholesterol levels. 
The Amlodipine/losartan group were significantly younger 
than the other two groups (P=0.03).
 Among the study population, baseline systolic and 
diastolic blood pressures were slightly higher in men than 
women but this difference was not significant as shown 
by  (P=0.79) for systolic blood pressure and (P=0.92) for 
diastolic blood pressure. No significant difference was 
observed between age of men and women in this study 
(P=0.18).  
Independent t-test revealed no significant difference in 
age between diabetic and non-diabetic patients (P=0.93). 
Also no significant difference was found in mean systolic 
and diastolic blood pressures between diabetic and non 
diabetic cases; (P=0.81) for systolic blood pressure and 
(P=0.52) for diastolic blood pressure. Among the 99 
diabetic patients there was no difference between the 
number of men and women (P=0.84). Diabetic patients 
used to smoke significantly more than the non-diabetics 
(38.4% of diabetics and 16.6% of non- diabetics were 
smokers) (P<0.01). Chi-square test was used to identify the 
relationship between diabetes and high serum cholesterol 
levels. High serum cholesterol levels were detected in 
94(96%) of diabetics which was significantly higher than 
6(1.6%) of non-diabetics (P<0.01). Metabolic syndrome 
was found in 92 (25.5%) of non-diabetics while none of the 
diabetics exhibited metabolic syndrome, which was found 
to be significantly higher (P<0.01). In respect of response 
to treatment there was no relationship among diabetics (P 
=0.57).
There was no relationship between response to treatment 
and gender, smoking, serum cholesterol level, metabolic 
syndrome and history of diabetes (Table 2).
There was a significant difference in systolic blood 
pressure reductions between the three treatment groups 
(P<0.001). There was also a significant difference between 
groups in reducing diastolic blood pressure (P<0.01). 
The highest systolic blood pressure reduction was found 
in treatment with Amlodipine/losartane followed by 
amlodipine/HCTZ and losartane alone (Table 3). The 
ANCOVA analysis revealed that only treatment regimen 
had a significant effect on blood pressure reduction 
(P=0.01).
Repeated measure test revealed significant difference 
in reduction rate of both systolic and diastolic pressure 
(P<0.001). Repeated measure test also showed that there is 
a significant relation in interaction between the before and 
after blood pressures (P<0.001).
 
Discussion
Combination therapy is proved to have better effects 
on blood pressure control in patients with stage 2 
hypertension (9-12). It was previously shown that the 
effect of combination therapy would be five times greater 
than doubling the dose of a single antihypertensive drug 
(13). This study found that all combinations resulted in 
38% reduction in systolic blood pressure. A recent study 
performed to compare the effect of Amlodipine/Losartan 
(5mg/100mg) combination therapy with single therapy 
with Amlodipine in Korea reported response rate of 90% 
for Amlodipine/Losartan treatment (14). Although a lower 
dose of Losartan was administered in this study, 89% 
response rate was acheived with Amlodipine/Losartan 
treatment. This finding indicates that in combination 
therapy with Amlodipine, the dose of Losartan can be 
reduced by 50% to achieve similar response rate when 
administered at 100mg bid. In this study, response to 
treatment in Amlodipine/HCTZ treatment group was 
72% that was similar to the study by Oparil et al (1996) 
responce rate of 71% (15). Response rate to Losartan/
HCTZ was 54% in this study. In a study by Bonner et al. 
(2009) response rate to combination therapy with 100mg 
Losartan plus 25mg HCTZ in stage 1 hypertensive patients 
was 53.8%.(16) In our study reducing Losartan dose by 
half, if combined with HCTZ, will not affect the response 
rate to combination therapy. 
Amlodipine/losartane combination therapy resulted in the 
highest systolic blood pressure reduction (20.5%) in this 
study. In a study by Kim et al. (17) systolic BP was reduced 
by 22.1% after 8 week treatment with 50mg Amlodipine/
Losartan treatment. Although in their study Losartan was 
administered at a higher dose (50mg compared with 25mg 
in our study). This difference can be due to the usage of 
higher losartane doses in the Kim et al.(17) study or a 
larger study population in this study (73 patients in Kim et 
al. study vs 164 patients in this study). In this study systolic 
blood pressure was reduced significantly with amlodipine/
losartane combination therapy. Systolic BP reduction with 
Losartan/HCTZ combination therapy was reported 15% in 
the Bonner et al. (16) study, which was performed on a 
larger population (n=4143) with the mean BP being in the 
range of stage 1 hypertension.(16) Systolic BP was reduced 
by 9% in Opal et al. (15) study, where the mean systolic BP 
was 159.0 mmHg which was lower than 169.88 mmHg in 
this study. 
In this study combination therapy with Losartan/HCTZ 
resulted in the highest (33.3%) reduction in diastolic BP. In 
the study by Bonner et al. (16), combination therapy with 
Losartan/HCTZ resulted in 12.9% reduction in diastolic 
BP which might be due to the study population, stage 1 
hypertensive patients. (16) In this study combination 
therapy with Amlodipine/Losartan resulted in 28.2% 
reduction in diastolic BP. In the study by Kim et al. (17) 
diastolic BP was reduced by 15.5% after 8 weeks treatment 
with Amlodipine/Losartan. The findings of this study 
revealed that Amlodipine/Losartan could result in a more 
reduction in diastolic BP (17% vs 15.5% in the study by 
Kim et al.) (17). No recent study was found to compare 
the effect of ARB/HCTZ with CCB/HTCZ. The results 
of this study indicated that CCB/HCZ combination might 
not be a useful combination for reducing BP in stage 2 
hypertension.
One of the limitations of this study was that there was 
no control on patients’ lifestyle including usual physical 
activity and food or drink intakes. It is recommended that 
further controlled trials be performed by selecting matched 
cases with similar lifestyle and BP.
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